APA (7th ed.) Citation

Soberanis Pina, P., Oza, A., Dhani, N., Wang, L., Grant, R., Garg, V., . . . Lheureux, S. (2024). 763P Re-VOLVE: Phase II trial in women with ovarian cancer progressing post-PARP-inhibitor with treatment adapted to real-time assessment of evolving genomic resistance. Annals of Oncology, 35, S577. https://doi.org/10.1016/j.annonc.2024.08.824

Chicago Style (17th ed.) Citation

Soberanis Pina, P.D., et al. "763P Re-VOLVE: Phase II Trial in Women with Ovarian Cancer Progressing Post-PARP-inhibitor with Treatment Adapted to Real-time Assessment of Evolving Genomic Resistance." Annals of Oncology 35 (2024): S577. https://doi.org/10.1016/j.annonc.2024.08.824.

MLA (9th ed.) Citation

Soberanis Pina, P.D., et al. "763P Re-VOLVE: Phase II Trial in Women with Ovarian Cancer Progressing Post-PARP-inhibitor with Treatment Adapted to Real-time Assessment of Evolving Genomic Resistance." Annals of Oncology, vol. 35, 2024, p. S577, https://doi.org/10.1016/j.annonc.2024.08.824.